Poor exploratory biomarker pathology wastes tissue and samples, produces misleading signals, and leads to delayed or wrong research decisions—causing downstream setbacks in translational programs. Senior pathology scientist–led advisory guidance delivers confidence in biomarker interpretation, preserves biological signal, enables clearer go/no-go decisions, and reduces uncertainty in early biomarker strategy.
This advisory service brings pathology judgment into biomarker decisions through tissue handling, block/slide management, sectioning strategy, staining approach, and interpretation guidance. The result is risk reduction, decision support, and clarity that prevents wasted resources and supports sound research direction. This work is exploratory, research-use, and upstream of regulated clinical trials—advisory and decision support, not lab execution or diagnostics.
Ensure tissue handling and fixation quality support reliable biomarker assessment, preventing wasted analysis on compromised samples
Systematic block and slide management ensures traceable interpretation and prevents mislinked cases that derail biomarker programs
Sectioning strategy that enables reproducible interpretation across samples, reducing variability that compromises research decisions
Marker and staining strategy that maximizes biological insight and minimizes misleading signals that lead to wrong conclusions
Interpretation guidance that distinguishes signal from artifact, contextualizing findings biologically to support confident biomarker strategy
"In exploratory biomarker research, the difference between a breakthrough and a dead end is often a single pathology judgment call."
We bring expert pathology judgment into your biomarker decisions. This is advisory partnership built on trust and judgment, not process and tasks.
We clarify biomarker questions and tissue context to identify where pathology judgment matters most
We evaluate tissue, blocks, slides, and staining strategy through a pathology scientist lens
We provide expert evaluation of findings and biological context to support sound decisions
We deliver written guidance on what to fix and next steps, informed by pathology judgment
This is advisory and consultative only. It is non-diagnostic, non-regulated, and does not include clinical trial endpoint validation. This work is upstream of formal development and regulatory workflows.
We review your study goals, available tissues, existing protocols, and constraints. This initial assessment identifies gaps, risks, and optimization opportunities.
We evaluate your current workflows, sample handling, assay performance, or pathology data quality. This identifies failure modes and decision points.
We deliver concrete outputs—protocols, SOPs, review reports, or workflow frameworks—with implementation guidance and follow-up support as needed.